These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 14568007)

  • 1. Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications.
    Metz TO; Alderson NL; Thorpe SR; Baynes JW
    Arch Biochem Biophys; 2003 Nov; 419(1):41-9. PubMed ID: 14568007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. Mechanism of action of pyridoxamine.
    Onorato JM; Jenkins AJ; Thorpe SR; Baynes JW
    J Biol Chem; 2000 Jul; 275(28):21177-84. PubMed ID: 10801874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pyridoxamine traps intermediates in lipid peroxidation reactions in vivo: evidence on the role of lipids in chemical modification of protein and development of diabetic complications.
    Metz TO; Alderson NL; Chachich ME; Thorpe SR; Baynes JW
    J Biol Chem; 2003 Oct; 278(43):42012-9. PubMed ID: 12923193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation.
    Voziyan PA; Metz TO; Baynes JW; Hudson BG
    J Biol Chem; 2002 Feb; 277(5):3397-403. PubMed ID: 11729198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes.
    Stitt A; Gardiner TA; Alderson NL; Canning P; Frizzell N; Duffy N; Boyle C; Januszewski AS; Chachich M; Baynes JW; Thorpe SR
    Diabetes; 2002 Sep; 51(9):2826-32. PubMed ID: 12196477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats.
    Alderson NL; Chachich ME; Youssef NN; Beattie RJ; Nachtigal M; Thorpe SR; Baynes JW
    Kidney Int; 2003 Jun; 63(6):2123-33. PubMed ID: 12753299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel inhibitors of glycation and AGE formation.
    Rahbar S
    Cell Biochem Biophys; 2007; 48(2-3):147-57. PubMed ID: 17709884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat.
    Degenhardt TP; Alderson NL; Arrington DD; Beattie RJ; Basgen JM; Steffes MW; Thorpe SR; Baynes JW
    Kidney Int; 2002 Mar; 61(3):939-50. PubMed ID: 11849448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reaction of pyridoxamine with malondialdehyde: mechanism of inhibition of formation of advanced lipoxidation end-products.
    Kang Z; Li H; Li G; Yin D
    Amino Acids; 2006 Feb; 30(1):55-61. PubMed ID: 15990947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modification of proteins in vitro by physiological levels of glucose: pyridoxamine inhibits conversion of Amadori intermediate to advanced glycation end-products through binding of redox metal ions.
    Voziyan PA; Khalifah RG; Thibaudeau C; Yildiz A; Jacob J; Serianni AS; Hudson BG
    J Biol Chem; 2003 Nov; 278(47):46616-24. PubMed ID: 12975371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of antioxidants and ACE inhibition on chemical modification of proteins and progression of nephropathy in the streptozotocin diabetic rat.
    Alderson NL; Chachich ME; Frizzell N; Canning P; Metz TO; Januszewski AS; Youssef NN; Stitt AW; Baynes JW; Thorpe SR
    Diabetologia; 2004 Aug; 47(8):1385-95. PubMed ID: 15309289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitors of advanced glycation end product formation and neurovascular dysfunction in experimental diabetes.
    Cameron NE; Gibson TM; Nangle MR; Cotter MA
    Ann N Y Acad Sci; 2005 Jun; 1043():784-92. PubMed ID: 16037306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical studies of advanced glycation end product inhibitors and diabetic kidney disease.
    Williams ME
    Curr Diab Rep; 2004 Dec; 4(6):441-6. PubMed ID: 15539009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Müller glial dysfunction during diabetic retinopathy in rats is linked to accumulation of advanced glycation end-products and advanced lipoxidation end-products.
    Curtis TM; Hamilton R; Yong PH; McVicar CM; Berner A; Pringle R; Uchida K; Nagai R; Brockbank S; Stitt AW
    Diabetologia; 2011 Mar; 54(3):690-8. PubMed ID: 21116609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis of a novel radical trapping and carbonyl group trapping anti-AGE agent: a pyridoxamine analogue for inhibiting advanced glycation (AGE) and lipoxidation (ALE) end products.
    Culbertson SM; Enright GD; Ingold KU
    Org Lett; 2003 Jul; 5(15):2659-62. PubMed ID: 12868883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New potential agents in treating diabetic kidney disease: the fourth act.
    Williams ME
    Drugs; 2006; 66(18):2287-98. PubMed ID: 17181372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pyridoxamine, an inhibitor of protein glycation, in relation to microalbuminuria and proinflammatory cytokines in experimental diabetic nephropathy.
    Elseweidy MM; Elswefy SE; Younis NN; Zaghloul MS
    Exp Biol Med (Maywood); 2013 Aug; 238(8):881-8. PubMed ID: 23970406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage.
    Voziyan PA; Hudson BG
    Cell Mol Life Sci; 2005 Aug; 62(15):1671-81. PubMed ID: 15905958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of early renal disease, dyslipidaemia and lipid peroxidation in STZ-diabetic rats by LR-9 and LR-74, novel AGE inhibitors.
    Figarola JL; Scott S; Loera S; Xi B; Synold T; Weiss L; Rahbar S
    Diabetes Metab Res Rev; 2005; 21(6):533-44. PubMed ID: 15818713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renoprotective and lipid-lowering effects of LR compounds, novel advanced glycation end product inhibitors, in streptozotocin-induced diabetic rats.
    Figarola JL; Scott S; Loera S; Xi B; Synold T; Rahbar S
    Ann N Y Acad Sci; 2005 Jun; 1043():767-76. PubMed ID: 16037304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.